2. Свирновский А.И. Резистентность опухолевых клеток к терапевтическим воздействиям как медико-биологическая проблема? Международные обзоры: клиническая практика и здоровье. 2014. С. 15–38.

3. Luo Ch., et al. Efcacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials. Stem. Cell Res Ther. 2022;13:123. Doi: 10.1186/s13287-022-02802-6.

4. Passweg J.R., Baldomero H., Ciceri F., et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplant. 2023;58:647–58. Doi: 10.1038/s41409-023-01943-3.

5. Грицаев С.В., Кузяева А.А., Волошин С.В. и др. Заготовка трансплантата для аутологичной трансплантации гемопоэтических стволовых клеток онкогематологическим больным: частота и причины. Русский медицинский журнал. 2013;1:30–5.

6. To L.B., Levesque J.P., Herbert K.E. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118:4530–40.

7. Kim M.G., Han N., Lee E.K., Kim T. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone Marrow Transplant. 2015;50:523–30.

8. Bruns I., Steidl U., Fischer J.C., et al. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematol. 2008;93:347–55.

9. Lapidot T., Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 2002;30(9):973–81.

10. Schmitt M., et al. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G‐CSF. Vox sanguinis. 2016;111(2):178–86.

11. Bakanay Ş.M., Demirer T. Novel agents and approaches for stem cell mobilization in normal donors and patients. Bone Marrow Transplant. 2012;47(9):1154–63.

12. Bruns .I, Steidl U., Kronenwett R., et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+progenitors in patients with multiple myeloma. Transfusion. 2006;46:180–85.

13. Fruehauf S., Klaus J., Huesing J., et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant. 2007;39:743–50.

14. Herbert K.E., Gambell P., Link E.K., et al. Peg filgrastim compared with filgrastim for cy tokine-alone mobilization of autologous haema topoietic stem and progenitor cells. Bone Marrow Transplant. 2013;48:351–56.

15. Hosing C., Qazilbash M.H., Kebriaei P., et al. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol. 2006;133:533–37.

16. Isidori A., Tani M., Bonifazi F., et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematol. 2005;90:225–31.

17. Nosari A., Cairoli R., Ciapanna D., et al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytincontaining regimens. Bone Marrow Transplant. 2006;38:413–16.

18. Willis F., Woll P., Theti D., et al. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours. Bone Marrow Transplant. 2009;43:927–34.

19. Kuan J.-W., et al. A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization. Transfus Apher Sci. 2015;53(2):196–204.

20. Russell N., et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy. Haematol. 2008;93(3):405–12. Doi.org/10.3324/haematol.11287.

21. Costa L.J., Kramer C., Hogan K.R. Pegfilgrastim versus filgrastim based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012;52(11):2375–81. 2995.2012.03579.x.

22. Flomenberg N., DiPersio J., Calandra G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol. 2005;114(4):198–205. Doi: 10.1159/000088410.

23. Нестерова Е.С., Сайдуллаева А.Ф., Шерстнев Д.Г. и др. Эффективность и безопасность применения препарата эмпэгфилграстим (Экстимия®, БИОКАД) у пациентов с лимфопролиферативными заболеваниями, получающих цитотоксическую терапию: результаты второго промежуточного анализа многоцентрового ретроспективно-проспективного наблюдательного пострегистрационного исследования LEGERITY. Современная онкология. 2022;24(1):80–8.

24. Wuchter P., Ran D., Bruckner T. Poor Mobilization of Hematopoietic Stem Cells Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation. Biol Blood Marrow Transplant. 2010;16:490–99. Doi: 10.1016/j.bbmt.2009.11.01.

25. Cesana C., Carlo-Stella C., Regazzi E., et al. CD34+ cells mobilized by cyclophosphamide and granulocyte colony stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. Bone Marrow Transplant. 1998;21:561–8.